Cargando…

A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US

INTRODUCTION: Sugammadex rapidly reverses the effects of rocuronium- and vecuronium-induced neuromuscular blockade (NMB), offering a more complete and predictable NMB recovery than cholinesterase inhibitors. Despite clinical benefits, cost pressures on hospital budgets influence the choice of the NM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yiling, Bash, Lori D., Saager, Leif
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107065/ https://www.ncbi.nlm.nih.gov/pubmed/33871823 http://dx.doi.org/10.1007/s12325-021-01701-1

Ejemplares similares

Clinical Impact of Sugammadex in the Reversal of Neuromuscular Blockade
por: Goodner, Joshua A, et al.
Publicado: (2021)

Sugammadex: Appropriate Use in the Context of Budgetary Constraints
por: Cammu, Guy
Publicado: (2018)

Should we Routinely Reverse Neuromuscular Blockade with Sugammadex in Patients with a History of Heart Transplantation?
por: Yuki, Koichi, et al.
Publicado: (2020)

Economic impact of improving patient safety using Sugammadex for routine reversal of neuromuscular blockade in Spain
por: Martinez-Ubieto, J., et al.
Publicado: (2021)

Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings
por: Bash, Lori D., et al.
Publicado: (2021)

Profile of sugammadex for reversal of neuromuscular blockade in the elderly: current perspectives
por: Carron, Michele, et al.
Publicado: (2017)

Neuromuscular Blockade Agents Reversal with Sugammadex Compared to Neostigmine in the Living Kidney Donors
por: Quang, Thuy Luu, et al.
Publicado: (2019)

Negative Pressure Pulmonary Edema after Reversing Rocuronium-Induced Neuromuscular Blockade by Sugammadex
por: Suzuki, Manzo, et al.
Publicado: (2014)

Sugammadex, a Neuromuscular Blockade Reversal Agent, Causes Neuronal Apoptosis in Primary Cultures
por: Palanca, José M., et al.
Publicado: (2013)

Sugammadex versus neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients
por: Woo, Tiffany, et al.
Publicado: (2013)

Sugammadex to Reverse Neuromuscular Blockade in a Child with a Past History of Cardiac Transplantation
por: Miller, Karen, et al.
Publicado: (2017)

Sugammadex to reverse neuromuscular blockade and provide optimal conditions for motor-evoked potential monitoring
por: Trifa, Mehdi, et al.
Publicado: (2017)

Economic analysis of sugammadex versus neostigmine for reversal of neuromuscular blockade for laparoscopic surgery in China
por: Ren, Maodong, et al.
Publicado: (2020)

An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant
por: Paredes, Stephania, et al.
Publicado: (2023)

The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade
por: Cheong, Soon Ho, et al.
Publicado: (2015)

Successful Neuromuscular Blockade Reversal Using Sugammadex and Neostigmine Failed to Prevent Myasthenic Crisis After Emergency Surgery: A Case Report
por: Haddad, Daniel, et al.
Publicado: (2022)

Introduction of sugammadex as standard reversal agent: Impact on the incidence of residual neuromuscular blockade and postoperative patient outcome
por: Ledowski, Thomas, et al.
Publicado: (2013)

Reversal of rocuronium induced neuromuscular blockade using sugammadex in a patient with eclampsia treated by magnesium intraoperatively
por: Song, Sejin, et al.
Publicado: (2014)

Effects of dexamethasone and hydrocortisone on rocuroniuminduced neuromuscular blockade and reversal by sugammadex in phrenic nerve-hemidiaphragm rat model
por: Choi, Heyran, et al.
Publicado: (2019)

The efficacy and safety of sugammadex for reversing postoperative residual neuromuscular blockade in pediatric patients: A systematic review
por: Liu, Guangyu, et al.
Publicado: (2017)

Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients: A systematic review and meta-analysis
por: Won, Young Ju, et al.
Publicado: (2016)

Cardiac arrest after administration of sugammadex as neuromuscular blockade reversal agent and full recovery from anesthesia
por: Samara, Evangelia, et al.
Publicado: (2020)

A retrospective study of sugammadex for reversal of neuromuscular blockade induced by rocuronium in critically ill patients in the ICU
por: Bologheanu, Răzvan, et al.
Publicado: (2022)

Unexpected delayed reversal of rocuronium-induced neuromuscular blockade by sugammadex: A case report and review of literature
por: Wang, Hao-Chen, et al.
Publicado: (2022)

Reversal of rocuronium‐induced intense neuromuscular blockade by sugammadex in Korean children: A pharmacokinetic and pharmacodynamic analysis
por: Ji, Sang‐Hwan, et al.
Publicado: (2022)

Conventional reversal of rocuronium-induced neuromuscular blockade by sugammadex in Korean children: pharmacokinetics, efficacy, and safety analyses
por: Ji, Sang-Hwan, et al.
Publicado: (2023)

Commentary on “An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant”
por: Chowdhury, Sumit Roy, et al.
Publicado: (2023)

The use of sugammadex in an infant with prolonged neuromuscular blockade - A case report -
por: Kim, Hyunho, et al.
Publicado: (2022)

Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center
por: Carron, Michele, et al.
Publicado: (2016)

Effects of age on sugammadex reversal of neuromuscular blockade induced by rocuronium in Chinese children: a prospective pilot trial
por: Zhang, Ruidong, et al.
Publicado: (2021)

Chronic exposure to dexamethasone may not affect sugammadex reversal of rocuronium-induced neuromuscular blockade: an in vivo study on rats
por: Park, Ha Yeon, et al.
Publicado: (2023)

Reply to the Commentary on “An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant”
por: Paredes, Stephania, et al.
Publicado: (2023)

Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy
por: Aouad, Marie T., et al.
Publicado: (2017)

Effects of Neostigmine and Sugammadex for Reversal of Neuromuscular Blockade on QT Dispersion Under Propofol Anesthesia: A Randomized Controlled Trial
por: Yamashita, Yusuke, et al.
Publicado: (2018)

Relationship between first-twitch depression and train-of-four ratio during sugammadex reversal of rocuronium-induced neuromuscular blockade
por: Kim, Kyo Sang, et al.
Publicado: (2016)

Efficacy and safety of sugammadex sodium in reversing rocuronium-induced neuromuscular blockade in children: An updated systematic review and meta-analysis
por: Zhou, Sheng, et al.
Publicado: (2023)

Sugammadex and Reversal of Neuromuscular Block in Adult Patient with Duchenne Muscular Dystrophy
por: Wefki Abdelgawwad Shousha, Ahmed Abdelgawwad, et al.
Publicado: (2014)

Sugammadex as a reversal agent for neuromuscular block: an evidence-based review
por: Schaller, Stefan Josef, et al.
Publicado: (2013)

Reversal of neuromuscular block with sugammadex in five heart transplant pediatric recipients
por: Carlos, Ricardo Vieira, et al.
Publicado: (2017)

Effect of protracted dexamethasone exposure and its withdrawal on rocuronium-induced neuromuscular blockade and sugammadex reversal: an ex vivo rat study
por: Oh, Seok Kyeong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oqgkle701dmj4rtikq0ort8hd8